To test this hypothesis, we vaccinated mice with the peptide Trp2180–188 from the melanoma antigen tyrosinase-related protein 2, either alone, with CpG-ODN, or in combination with both CpG-ODN and CD1d-HER2 fusion protein. This evidence concerns the gene CD1D and melanoma.